Early and Late Prognosis in Patients With Guillain-Barre Syndrome

NCT ID: NCT06041451

Last Updated: 2023-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-02

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter study(approximately three) with over 450 subjects.Clinical data were collected by consulting the patient's electronic history. The data included demographic information, blood biochemical markers, clinical characteristics and electromyography. All participants provided their written informed consent to participate in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Guillain-Barre Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

immunoglobulin group

This group of patients was treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days

Group Type EXPERIMENTAL

Intravenous Immunoglobulins, Human

Intervention Type DRUG

patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days

methylprednisolone group

This group of patients was treated with methylprednisolone 500 MG Injection

Group Type EXPERIMENTAL

Methylprednisolone 500 MG Injection

Intervention Type DRUG

patients were treated with methylprednisolone

control group

This group of patients was treated without immunoglobulin or hormone

Group Type NO_INTERVENTION

No interventions assigned to this group

mixed group

This group of patients was treated both with intravenous immunoglobulin and methylprednisolone.

Group Type EXPERIMENTAL

Intravenous Immunoglobulins, Human

Intervention Type DRUG

patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days

Methylprednisolone 500 MG Injection

Intervention Type DRUG

patients were treated with methylprednisolone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravenous Immunoglobulins, Human

patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days

Intervention Type DRUG

Methylprednisolone 500 MG Injection

patients were treated with methylprednisolone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients fulfilled clinical, biological, and electrophysiology criteria for Guillain-barre syndrome.

Exclusion Criteria

* nonidiopathic Guillain-barre syndrome and Miller Fisher syndrome
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital of Wenzhou Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Binbin Deng

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Binbin Deng, Doctor

Role: primary

+8613695720610

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Dengbinbin

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.